- October 14, 2020
Despite the challenges 2020 has presented, CX-011 is on schedule to enter clinical trials for mild to moderate osteoarthritis in mid-2021. Following successful scale up and validation, sufficient quantities of the therapeutic candidate were produced under strict Good Manufacturing Practices (GMP) guidelines to support the trial next year. In parallel, CarthroniX received positive regulatory feedback on its proposed path to the clinic and clinical protocol. These impressive developments represent major milestones for the program and sustain its progress toward first-in-human testing next year.